Navigation Links
Enigma Signs Real-Time PCR Licences With Applera
Date:2/7/2008

PORTON DOWN, England, February 7 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics systems, announces today that it has signed license agreements with Applera Corporation.

The licenses, signed 6 February 2008, include a Real-Time Instrument Patent License Agreement and an Application Kit License Agreement. These agreements provide Enigma with access under patents owned or controlled by Applera for real-time PCR thermal cyclers and real-time PCR methods and compositions in specific fields.

The Real-Time Instrument Patent License Agreement covers Enigma's current and pipeline instrument platforms of fully automated, real-time thermal cyclers across the commercial market sectors of research and applied markets. This agreement also provides Enigma with an option for a license in clinical diagnostics.

The Application Kit License Agreement covers a portfolio of important patents covering reverse transcription-based methods, real-time PCR detection process and 5' Nuclease assays and compositions, for use in fields excluding human diagnostics.

Financial terms were not disclosed.

John McKinley, Chairman of Enigma Diagnostics, said: "These licenses together with Enigma's extensive portfolio of molecular diagnostic patents and unique instrument platforms confirm Enigma's leading position within the global molecular diagnostics market and underpin the launch of its instruments in 2008."

Notes to Editors:

About Enigma Diagnostics

Enigma Diagnostics Limited is a private UK based company developing the next generation of rapid diagnostic instrument platforms for the detection and identification of infectious organisms, such as bacteria and viruses, in clinical, environmental and biological samples.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based and point-of-care tests. The Company is targeting a number of multi-billion pound markets, core among which are the clinical, defence and homeland security, and veterinary markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of-care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will build an in-house sales and marketing capability to direct distribution of its bespoke products and partner with market leaders where global penetration of markets is required.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents which represent over 15 years of UK Ministry of Defence funded research. Enigma's own R&D activities have added additional patents and design rights based upon its proprietary technologies to generate a portfolio of over 45-plus worldwide patents and patent applications dedicated to real-time PCR and wider rapid technologies of which over 26 have granted status. The patents are granted in a range of core territories. Information about Enigma is available at http://www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
3. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
6. Monsanto Company Signs Share Subscription Agreement With Devgen
7. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
8. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
9. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), a ... webinar on Performing Quality Investigations: Getting to Root Cause. This ... charge. , Incomplete investigations are still a major concern to the Regulatory Authorities ...
Breaking Biology Technology:
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):